Difference between revisions of "Filgrastim-sndz (Zarxio)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulate...") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (16 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). | + | Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation. The formulation of Filgrastim-sndz (Zarxio) differs from that of [[Filgrastim (Neupogen)]] in one inactive component.<ref name="insert">[https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe707775-a0ae-41b5-a744-28c41889fce8&type=display Filgrastim-sndz (Zarxio) package insert]</ref><ref>[[:File:Filgrastim-sndz.pdf | Filgrastim-sndz (Zarxio) package insert (locally hosted backup)]]</ref><ref>[http://zarxio.com/ Zarxio manufacturer's website]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: no known issues | <br>Extravasation: no known issues | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | ''Note that colony stimulating factors | + | ''Note that colony stimulating factors may be used for their adjuvant effect e.g. removing leukemia stem cells from their protective niches; but they are not thought to have inherent anti-cancer activity.'' |
==Patient drug information== | ==Patient drug information== | ||
| − | + | *[https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe707775-a0ae-41b5-a744-28c41889fce8&type=display Filgrastim-sndz (Zarxio) package insert]<ref name="insert"></ref> | |
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2015-03-06: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm436953.htm FDA Approved as a biosimilar] to US-licensed [[Filgrastim (Neupogen)|Neupogen]] for the five indications for which US-licensed [[Filgrastim (Neupogen)|Neupogen]] is approved: |
| + | **"Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever" | ||
| + | **"Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)" | ||
| + | **"Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)" | ||
| + | **"Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis" | ||
| + | **"Reduce the incidence and duration of sequelae of severe neutropenia (e.g.,fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia" | ||
| + | ==History of changes in EMA indication== | ||
| + | *2009-02-06: Initial authorization as Zarzio | ||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Zarxio, Zarzio | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| − | [[Category: | + | [[Category:Subcutaneous medications]] |
| − | |||
| − | [[Category: | + | [[Category:Granulocyte colony-stimulating factors]] |
| + | |||
| + | [[Category:EMA approved in 2009]] | ||
| + | [[Category:FDA approved in 2015]] | ||
| + | [[Category:Biosimilars]] | ||
| + | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 01:01, 29 June 2024
General information
Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation. The formulation of Filgrastim-sndz (Zarxio) differs from that of Filgrastim (Neupogen) in one inactive component.[1][2][3]
Route: SC
Extravasation: no known issues
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is used
Note that colony stimulating factors may be used for their adjuvant effect e.g. removing leukemia stem cells from their protective niches; but they are not thought to have inherent anti-cancer activity.
Patient drug information
History of changes in FDA indication
- 2015-03-06: FDA Approved as a biosimilar to US-licensed Neupogen for the five indications for which US-licensed Neupogen is approved:
- "Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever"
- "Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)"
- "Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)"
- "Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis"
- "Reduce the incidence and duration of sequelae of severe neutropenia (e.g.,fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia"
History of changes in EMA indication
- 2009-02-06: Initial authorization as Zarzio
Also known as
- Brand names: Zarxio, Zarzio